Phaseline

Targets › B7-H3

B7-H3: drug programs, companies and trials

2 programs from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: the race on B7-H3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer Center131I-omburtamab
Anti-B7-H3 monoclonal antibody labeled with iodine-131 for radioimmunotherapy
B7-H3Phase 2Desmoplastic Small Round Cell TumorJul 2027
Memorial Sloan Kettering Cancer Center177Lu-DTPA-omburtamab
Lutetium-177-labeled anti-B7-H3 monoclonal antibody conjugate
B7-H3Phase 1Recurrent MedulloblastomaJun 2030

Conditions

Desmoplastic Small Round Cell Tumor (1) Recurrent Medulloblastoma (1)

Modalities

antibody (2)

Companies

Memorial Sloan Kettering Cancer Center (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.